Zoetis (NYSE:ZTS) is an animal health company that was a spinoff from Pfizer. The company reported very strong quarterly earnings and issued solid 2018 guidance that was higher than Wall Street estimates. Zoetis remains well positioned to continue to increase share in the livestock and companion animal markets while being insulated from the drug pricing and healthcare reform issues pressuring the human pharmaceutical companies.
From Keeley All Cap Value Fund 1st quarter 2018 shareholder letter.
